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Abstract
Purpose Cholecystokinin 2 (CCK-2) receptor overexpres-
sion has been demonstrated in a high percentage of
medullary thyroid carcinomas (MTC). Analogous to so-
matostatin receptors, CCK-2 receptors might be viable
targets for radionuclide scintigraphy and/or radionuclide
therapy. Several CCK-2 receptor-binding radiopeptides
have been developed, and some have been carried through
into clinical studies. However, these studies are mostly
limited and difficult to compare. The aim of this study was
to evaluate the diagnostic and therapeutic potential of three
promising CCK-2 receptor-binding radiopeptides in
patients with MTC.
Methods 111In-DOTA-(D)Asp-Tyr-Nle-Gly-Trp-Nle-Asp-
Phe-NH2 (
111In-DOTA-CCK), a CCK analogue, and the
gastrin-based ligands 99mTc-N4-Gly-(D)Glu-(Glu)5-Ala-Tyr-
Gly-Trp-Met-Asp-Phe-NH2 (
99mTc-demogastrin 2) and
111In-DOTA-(D)Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2
(111In-DOTA-MG11) were each administered to the same
group of six patients. Planar images made at 3–5, 7 and
24 h p.i. were used for comparison of tumour visualisation
and renal uptake.
Results 99mTc-demogastrin 2 scintigraphy visualised all
known lesions and new lesions in four of six patients.
111In-DOTA-CCK and 111In-DOTA-MG11 on the other
hand missed several lesions; tumour uptake of these two
radiopharmaceuticals was quite low. Comparison of reten-
tion of renal activity showed no major differences between
the three radiopeptides.
Conclusion 99mTc-demogastrin 2 scintigraphy appeared most
promising as a diagnostic tool in patients with MTC. Further
studies are required to evaluate its value in patient manage-
ment. Direct comparisons of the compounds studied strongly
suggests that 111In-DOTA-CCK and 111In-DOTA-MG11
have less potential as imaging agents than 99mTc-
demogastrin 2. These DOTA-linked compounds are
considered unlikely to be useful for radionuclide therapy
because of low tumour uptake.
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Introduction
Medullary thyroid carcinoma (MTC) originates from
malignant de-differentiation of the calcitonin-producing
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parafollicular cells (C cells) in the thyroid. Elevated serum
calcitonin is a very sensitive and specific tumour marker for
MTC. It can indicate the presence of remaining or recurring
tumour after resection of the primary tumour. However,
with the available diagnostic imaging modalities [i.e.
computed tomography (CT), magnetic resonance imaging
(MRI), ultrasound (US), somatostatin receptor scintigraphy
(SRS), 18F-fluoro-2-deoxyglucose positron emission to-
mography (18F-FDG PET)] localisation of the recurrent
tumour or metastases (and surgical intervention) often is not
possible. In cases of distant metastases there is no well-
accepted treatment available. This makes the development
of both a sensitive diagnostic imaging modality and a
systemic therapy very important.
The high sensitivity of the commonly used pentagastrin
stimulation test suggests a widespread expression of
cholecystokinin 2/gastrin receptors (CCK-2 receptors) in
MTC and indeed autoradiographic studies demonstrated
CCK-2 receptors in 90% of MTCs (and in a high
percentage of several other tumours like small cell lung
cancer) [1]. These G protein-coupled receptors bind both
CCK and gastrin and might serve as targets for radio-
labelled CCK or gastrin analogues for both scintigraphy
and peptide receptor radionuclide therapy (PRRT), analo-
gous to the successful use of radiolabelled somatostatin
analogues in patients with tumours overexpressing somato-
statin receptors [2, 3],
Studies in patients with MTC have been performed with
both gastrin-like [4–7] and CCK-like peptides [8]. Unfor-
tunately, comparison of the results of these studies is
difficult because of the different protocols applied in non-
comparable and sometimes small groups of patients.
We decided to investigate and compare three promising
CCK-2 receptor-binding peptides in patients with MTC.
First: 111In-DOTA-(D)Asp-Tyr-Nle-Gly-Trp-Nle-Asp-Phe-
NH2 (
111In-DOTA-CCK), this analogue showed similar
results in animal studies as the 111In-DTPA counterpart,
which has already been tested in patients [8]. However, the
DOTA chelator allows stable radiolabelling with thera-
peutic nuclides such as 90Y and 177Lu and might enable
PRRT. Second: the gastrin-like peptide 99mTc-N4-Gly-(D)
Glu1-(Glu)5-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 (
99mTc-
demogastrin 2) that showed very promising results for
scintigraphy in animal experiments and also in one patient
[7]. Third: 111In-DOTA-(D)Glu-Ala-Tyr-Gly-Trp-Met-
Asp-Phe-NH2 (
111In-DOTA-MG11) is the last peptide that
is included in this study. In a patient study by Béhé et al.
90Y-DTPA-(D)Glu1-(Glu)5-Ala-Tyr-Gly-Trp-Met-Asp-Phe-
NH2 (
90Y-DTPA-DGlu1-minigastrin), tested as a radionu-
clide therapy candidate, caused serious side effects,
including renal insufficiency and bone marrow toxicity
[5]. In animal studies, the DOTA-linked des-(Glu)5 truncated
analogue of minigastrin, 111In-DOTA-MG11, showed similar
affinity for CCK-2 receptors but significantly reduced renal
uptake in comparison with the respective full-length ana-
logue 111In-DOTA-DGlu1-minigastrin [9]. Due to its low
renal retention, this truncated analogue might have therapeu-
tic potential and therefore it was tested in patients showing
tumour uptake with one of the other CCK-2 receptor-binding
radioanalogues.
The aim of this study was to investigate the biodistribu-
tion and compare the diagnostic potential of the three
radiolabelled CCK-2 receptor-binding analogues and eval-
uate the therapeutic potential of the two 111In-DOTA
compounds in the same patients.
Materials and methods
Patients
MTC patients with elevated calcitonin levels after thyroid-
ectomy were sent to the Department of Nuclear Medicine
for tumour staging with CCK-2 receptor scintigraphy and/
or to investigate the possibility of PRRT with CCK-2
receptor-binding analogues. Patients underwent scintigra-
phy with 111In-DOTA-CCK and 99mTc-demogastrin 2. In
patients showing tumour uptake, 111In-DOTA-MG11 scin-
tigraphy was performed additionally with the aim of
localising the maximum possible number of tumour lesions
before operation and/or evaluating its potential for radio-
nuclide therapy in patients with distant metastases. Six
patients (five women and one man, age: 17–71 years,
median: 41 years) were tested with all three mentioned
radioligands and included in this study. Calcitonin levels
before administration of the first peptide ranged from 0.23
to 131 μg/l (mean: 38.4 μg/l). Use of 111In-DOTA-CCK
and 99mTc-demogastrin 2 in patients was approved by the
Erasmus MC Medical Review Ethics Committee. 111In-
DOTA-MG11 scintigraphy was performed on a compas-
sionate use basis as allowed by the Erasmus MC Medical
Review Ethics Committee. All patients gave written
informed consent before each administration. The maximal
interval between the three scintigrams was 5 weeks in five
patients and 4 months in one patient (patient 1).
Peptide handling, radiolabelling and radiochemical analysis
Radiolabelling of DOTA-MG11 (Radiological Chemistry,
University Hospital Basel, Switzerland) and DOTA-CCK
(BioSynthema, St. Louis, MO, USA) was performed as
described earlier [10]. The procedure was optimised to
prevent oxidation and radiolysis. Likewise, the procedure
of radiolabelling demogastrin 2 (NCSR “Demokritos”,
Athens, Greece) [7] was slightly modified to achieve higher
specific activity while preventing oxidation and radiolysis
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[11]. Formation and radiochemical purity of the three
radiopharmaceuticals were analysed by a combination of
instant thin-layer chromatography (ITLC) and high-
performance liquid chromatography (HPLC). For all three
radiopharmaceuticals an administration of 10 μg peptide
with the maximal achievable amount of radioactivity was
aimed at, resulting in administered doses as described
below.
Administration and imaging
The administered activities were: 216±19 MBq 111In-DOTA-
CCK (11.1±0.6 µg peptide), 773±97 MBq 99mTc-demogas-
trin (9.5±1.5 µg) and 186±34 MBq 111In-DOTA-MG11
(10.8±1.7 µg). The radiopharmaceuticals were administered
intravenously over a 5-min period. Blood pressure and heart
rate were monitored and patients were asked to report side
effects.
Imaging was performed with a dual head camera (Prism
2000XP, Philips, Cleveland, OH, USA) equipped with
either a medium-energy (111In) or a low-energy high-
resolution (99mTc) collimator. Dynamic images of the upper
abdomen or known tumour lesions were obtained during
30 min after injection. Total body images of 10 min
acquisition time were made at 40 min post (start of)
injection (p.i.). Static spot views were obtained at 1, 3–5
and 24 h p.i. and also at 7 h p.i. in most cases. Acquisition
time of most images was 15 min; only at 24 h p.i. was the
scan time for the 99mTc-labelled compound 30 min. SPECT
images of neck and upper abdomen were made at 4–5 h p.i.
and also at 24 h p.i. with the 111In-labelled radioligands.
Planar images of 3–5, 7 and 24 h p.i. were used for
comparison of the scintigraphy results.
Interpretation of the images
Four nuclear physicians, blinded for the agents used and the
locations of the known lesions, evaluated the scans
conjointly. Lesions that did not represent normal biodis-
tribution and persisted over time were judged as suspicious
for tumour localisation (“positive”). Lesions that were
barely visible and/or did not show persisting uptake over
time were judged as equivocal. After the random analysis
of scans per ligand, also a combination of series of the three
ligands was compared with regard to biodistribution and
pathological uptake.
Scintigraphic findings were correlated with diagnostic
investigations that had been performed earlier. In cases of
equivocal or positive lesions in regions without known tumour
lesions, correlating imaging was performed. For neck lesions
US investigations were performed by an experienced radiol-
ogist (AvdL) with knowledge of the location of the lesions on
the CCK-2 receptor scintigrams. If corresponding lymph
nodes could be localised, fine-needle aspiration cytology was
performed (if technically possible). For other unknown lesions
CTand/or MRI were performed which were interpreted by the
radiologist with knowledge of the affected organ using
standard radiological criteria for malignancy like enhance-
ment patterns, invasiveness, bone destruction and density
(CT) or signal intensity (MRI) of lesions. Thereafter, the CT
and MR images were correlated with the CCK-2 receptor
scintigrams.
Renal uptake was calculated according to the geometric
mean method using anterior and posterior planar views and
a standard with known activity. Data were corrected for
background activity and attenuation (based on CT data). In
each patient the same region was used for all calculations
(both time points of the three radioligands). If over-
projection of activity in other organs hampered the
measurement, total counts in the kidney were estimated
by multiplying the number of counts/pixel (in the part of
the kidney without overprojection) with the number of
pixels of the kidney (as defined on early images without
overprojection).
Analysis of blood and urine
Radioactivity in blood samples was measured with a
Packard COBRA auto-gamma counting system (Packard,
Meriden, CT, USA) and radioactivity in urine samples with
a dose calibrator. Blood samples were drawn at 10, 20, 30,
40, 60 and 90 min and 2, 4 and 24 h after start of injection.
Urine was collected during 24 h after injection. The
chemical status of the radioactive compounds in blood
and urine was analysed as a function of time using HPLC
techniques.
Calcitonin levels were determined by the standard
laboratory procedure in the hospital (radioimmunoassay,
upper normal value 0.14 μg/l) in blood samples taken
shortly before and at 2, 5 and 10 min after start of
administration of the radioligands.
Results
Administration
Administration of the radioligands was often followed by a
clear increase of serum calcitonin levels (Fig. 1) and was
sometimes associated with mild side effects; these were
different in the various patients. Side effects during adminis-
tration were increase of heart rate (maximum heart rate
105 bpm, rise only experienced by one patient), flushes (four
patients), mild pressure on the chest (two patients), mild
nausea (four patients, no vomiting), paraesthesia in the hands
(two patients) and in one patient some dizziness. In one patient
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(patient 5) 111In-DOTA-CCK caused the most side effects;
this was the only patient with calcitonin levels clearly higher
after administration of 111In-DOTA-CCK compared to
calcitonin levels after administration of the other radioligands
(Fig. 1). In three (of six) patients, 99mTc-demogastrin 2
caused the most side effects and two patients did not have
any side effects at all. All side effects were mild and
disappeared spontaneously within 10 min after administra-
tion (heart rate normalised within 2 min). Two patients
previously had a pentagastrin stimulation test and both
judged the side effects of that test to be far more severe.
Biodistribution
The dynamic series obtained during the first 30 min p.i.
showed radioactivity in blood pool, kidneys and stomach in
all patients. Visualisation of the (strong CCK-2 receptor-
positive [12]) stomach was clearest with 99mTc-demogastrin
2. Total body images showed accumulation in joint regions
(such as shoulders, hips, lumbar spine), nipples and in
breasts of premenopausal women as well. In some patients
tumour uptake was already visible in this early time frame.
On the 3–4 h p.i. images, clear visualisation of the stomach
was observed, especially with 99mTc-demogastrin 2. Besides
uptake in joint regions, breasts and nipples and the activity in
the kidneys and bladder, there was also radioactivity in the
bowel. 111In-DOTA-CCK showed some activity in the liver,
111In-DOTA-MG11 showed less liver activity and with
99mTc-demogastrin 2 the liver was hardly visible. At this
time point more tumour lesions were recognised, best with
99mTc-demogastrin 2. Physiological activity in joint regions
and breasts decreased over time, whereas activity in tumour
lesions was more stable. This resulted in easier interpretation
of the images at later time points, especially at 7 h p.i.
(Fig. 2). At 24 h p.i. most tumour lesions were still visible,
even with 99mTc-demogastrin 2, partly due to the very low
background activity.
Lesion detection
99mTc-demogastrin 2 visualised all known lesions. In
addition this analogue visualised in four patients unknown
lesions in the neck (two patients), brain (one patient), bone
Fig. 1 Calcitonin levels (highest measured concentrations) after
administration of the radioligands. Calcitonin levels in percentages
of the initial calcitonin measurements (set at 100%)
Fig. 2 Scintigrams of patient 6
(anterior view): 1st row 99mTc-
demogastrin 2, 2nd row 111In-
DOTA-MG11 and 3rd row
111In-DOTA-CCK at 4, 7 and
24 h p.i., respectively.
Decreasing activity in
sternoclavicular (SC) joints over
time simplifying interpretation
(especially for111In-DOTA
compounds). Best tumour
visualisation with 99mTc-
demogastrin 2 at 7 h p.i. Tumour
lesions in neck marked with
closed arrows, left SC joint with
open arrows
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(one patient) and/or liver (one patient). With the other two
compounds several known lesions were missed and fewer
new lesions were discovered. New liver lesions in one
patient were not visible with 111In-DOTA-CCK; neck
lesions in another patient could only be recognised on the
99mTc-demogastrin 2 scan. An unknown lesion in the brain
was only retrospectively seen with the two 111In-DOTA
compounds (after localisation with 99mTc-demogastrin 2).
In each of the four patients with new lesions at least one of
the new lesions was confirmed by additional imaging with
US, CT or MRI. A neck lesion only visible on 99mTc-
demogastrin 2 scintigraphy was confirmed by US-guided
fine-needle aspiration cytology as a 6-mm true positive
lesion (patient 4). In patient 2 cytologic investigation of the
brain lesion was not possible because of the location of the
lesion. MRI images could not differentiate between tumour
or pineal cyst. Results are listed in Table 1. Figures 3 and 4
show examples of the comparative images of the three
radiopharmaceuticals in two of the six patients studied.
Renal uptake
Visually there were no clear differences in renal uptake
between the three compounds; the stomach (CCK-2
receptor-positive) to kidney ratio seemed best with 99mTc-
demogastrin 2 (Fig. 5). Renal uptake calculation was
hampered by overprojection of activity in stomach and bowel.
To recognise important differences in renal uptake, regions
without overprojection of other activity-accumulating organs
were chosen. In three patients these regions were available for
all three radioligands (and time points), and in these patients
renal uptake values were in the same range (uptake in left
kidney: for 111In-DOTA-CCK, 111In-DOTA-MG11 and
99mTc-demogastrin 2, respectively, 0.62±0.27, 0.37±0.19
and 0.48±0.22%ID at ±4 h p.i. and 0.25±0.10, 0.16±0.04
and 0.27±0.07%ID at ±24 h p.i.).
Radioactivity in blood and urine
Serum radioactivity and urine radioactivity of all three
radioligands were analysed in five patients; detailed results
are described elsewhere [11]. Briefly, there were neither
statistically significant differences in the decrease of serum
radioactivity nor in the (very fast) urinary excretion of
radioactivity for the three compounds. HPLC blood analyses,
however, showed clear differences in the degradation rates of
the analogues. In blood samples taken at 10 min after start of
administration 64±6% of 99mTc-demogastrin 2 was still
intact. At the same early time point only 38±9% of 111In-
DOTA-CCK and 9±3% of 111In-DOTA-MG11 was still
intact.
Discussion
Patients with residual or recurrent MTC after surgery can be
potentially cured if lesions are limited to the neck region.
Inasmuch as available diagnostic modalities often fail to
Table 1 Lesions visualised using the three radiopharmaceuticals
99mTc-demogastrin 2 111In-DOTA-MG11 111In-DOTA-CCK
Patient 1 Neck None Neck equivocal
Calcitonin 15 μg/l Liver
Patient 2a Neck/mediastinum Neck/mediastinum Neck/mediastinum
Calcitonin 49 μg/l Brain (unknown, MRI+a) Brain equivocal (retrospective) Brain (retrospective)
Patient 3b Neck (4 lesions, 2 unknownb) Neck (4 lesions, 2 unknownb) Neck (2 lesions)
Calcitonin 0.33 μg/l
Patient 4 Neck (2 lesions, 1 unknown) None None
Calcitonin 0.23 μg/l Unknown lesion: FNA: MTC+
Patient 5c Neck Neck Neck
Calcitonin 35 μg/l Mediastinum Mediastinum Mediastinum
Liver (unknown, MRI+) Liver (unknown, MRI+)
Bone (unknown, CT+) Bone (unknown, CT+) Bone (unknown, CT+)
Patient 6c Neck Neck Neck
Calcitonin 131 μg/l Lungs Lungs Lungs
Liver Liver Liver
Bone Bone Bone
aMRI: pineal cyst possible. Lesion with 111 In-DOTA-MG11 and 111 In-DOTA-CCK missed on initial reading
b Not all lesions could be confirmed by US
c Lesions in patients 5 and 6 best visible with 99m Tc-demogastrin 2 (Figs. 2 and 4)
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detect the tumour lesions in patients with slightly elevated
serum calcitonin levels, a more sensitive modality is
needed. Furthermore, there is a strong impetus for the
development of PRRT, based on targeting CCK-2 receptors,
because there is currently no effective therapy available for
patients with distant metastases of MTC.
Comparison of the results of several studied CCK-2
receptor-binding compounds [4–8] used in various and
sometimes small patient groups is of limited value.
Nevertheless, the promising results of a number of
preclinical, as well as a few clinical studies using radio-
labelled CCK-2 receptor-binding peptides, have shown that
these compounds might be useful in the management of
patients with MTC (and possibly other CCK-2 receptor-
positive tumours [1, 13]). We therefore carried out a more
controlled study that allows for the direct comparison of
promising CCK-2 receptor-targeted analogues in the same
patients in an attempt to find the best analogue for tumour
localisation and test the potential of the two 111In-DOTA
compounds for PRRT.
Comparing the results of the analogues tested, 99mTc-
demogastrin 2 scintigraphy showed the most promising
results. All known tumour lesions were visualised and in
four of six patients new lesions were discovered. Even in
two patients with rather low calcitonin levels (patients 3 and
4) lesions were visible. Both 111In-DOTA-MG11 and 111In-
DOTA-CCK were less suitable for scintigraphy as image
quality was inferior and several lesions were missed that
were observed with 99mTc-demogastrin 2. The scintigraphic
results of the 111In-labelled peptides were disappointing as
not only the sensitivity but also the uptake in the visible
lesions was limited and appeared to be insufficient for
Fig. 3 Scintigrams of patient 1
(anterior and posterior views):
1st row 99mTc-demogastrin 2 at
4 h and 24 h, 2nd row 111In-
DOTA-MG11 at 4 h and 24 h
and 3rd row 111In-DOTA-CCK
at 4 h and 24 h. Tumour lesions
(and stomach) are best visible
on 99mTc-demogastrin 2
scintigraphy; some lesions are
marked with arrows
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radionuclide therapy in these tumours, especially considering
that MTC is reported to be radioresistant [14].
The variation in diagnostic performance among the three
tracers is probably the combined result of several parameters.
It is well known that 99mTc has better imaging properties than
111In. Furthermore, a higher specific activity labelling could
be achieved with 99mTc-demogastrin 2 resulting in a higher
injected activity (labelled to 10 μg of the peptide). Another
important parameter probably is the difference in the in vivo
stability of the three radioligands. The stability of 111In-
DOTA-MG11 was unexpectedly low. This peptide was
previously reported to be stable in ex vivo human serum
[9], but HPLC results of blood samples taken at 10 min after
start of the administration showed that only approximately
10% of the original peptide was still intact. In contrast,
99mTc-demogastrin 2 was more stable; HPLC showed that on
average more than 60% of the radioligand was intact at the
same time point. Recently Good et al. reported a decreased
mean lifetime and lower tumour uptake of 111In-DOTA-
MG11 in comparison with 111In-DTPA-DGlu1-minigastrin
[15]. Therefore, the diagnostic efficacy of 111In-DOTA-MG11
might be inferior to that of 111In-DTPA-DGlu1-minigastrin [5,
6]. Gotthardt et al. reported a tumour detection rate of 87%
by scintigraphy using this compound in a group of 26 MTC
patients. Most of the patients included in that study, however,
had known metastases and in the group of patients with
occult disease (n=5) tumour lesions were found in only one
patient. A direct comparison between 111In-DTPA-DGlu1-
minigastrin and 99mTc-demogastrin 2 would be of interest.
The renal uptake of the three test compounds was also of
interest, considering the previous report by Béhé and Behr
[5], who observed that therapy with 90Y-DTPA-DGlu1-
minigastrin caused renal damage. Calculation of renal uptake
values was impaired by overprojection of activity in bowel
and stomach that changed over time. However, visual
evaluation and an estimation of renal uptake made clear that
the differences in renal uptake were far less than expected. In
particular, the renal uptake of 99mTc-demogastrin 2 was in
the same range as the uptake of 111In-DOTA-MG11 and
111In-DOTA-CCK, although in previous animal studies
kidney radioactivity levels were high in comparison with
111In-DOTA-MG11 and 111In-DOTA-CCK [7, 9, 16].
Béhé et al. [17] reported high uptake of 111In-DTPA-
DGlu1-minigastrin in the kidneys of mice. This renal uptake
could be significantly blocked by coinjection of polygluta-
Fig. 5 Scintigrams of patient 1
(untruncated posterior views,
24 h p.i.) to judge kidney uptake
(open arrows) in relation to
stomach uptake (closed arrows).
1st 99mTc-demogastrin 2, 2nd
111In-DOTA-MG11 and 3rd
111In-DOTA-CCK
Fig. 4 Scintigrams of patient 5 (anterior view, young woman with
known mastopathy): 1st row 99mTc-demogastrin 2, 2nd row 111In-
DOTA-MG11 and 3rd row 111In-DOTA-CCK at 4, 7 and 24 h p.i.,
respectively (activity in breast tissue decreasing over time). Clearest
visualisation of known tumour lesions in neck, lungs, liver and bone
with 99mTc-demogastrin 2 (some lesions marked with arrows)
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mic acids, whereas tumour uptake was not impaired,
resulting in a higher tumour to kidney ratio. If polyglutamic
acid coinjection is well tolerated by patients, this method
might be useful to reduce nephrotoxicity after PRRT with
90Y-DTPA-DGlu1-minigastrin or other gastrin-like analogues.
The commonly used plasma expander Gelofusin® might also
be useful for lowering renal uptake. Gotthardt et al. reported
a significant reduction of renal accumulation (45%) of 111In-
DTPA-DGlu1-minigastrin in rats using Gelofusin® [18].
Potential bone marrow toxicity of 90Y-DTPA-DGlu1-minigas-
trin might remain a cause of concern, because the reported
activity in blood and other organs was not lower after use of
polyglutamic acids [16]. These various findings imply that
further improvement can be made to enhance the efficacy of
CCK-2 receptor-binding ligands for PRRT. As 99mTc-
demogastrin 2 showed most tumour lesions and renal uptake
of this analogue was lower than expected, 188Re-demogastrin
2 might be one of the potential radiopharmaceuticals which
deserves further investigation.
From our results we conclude that: (1) 99mTc-demogastrin
2 scintigraphy appears to be a very promising diagnostic tool
in patients with evidence of recurrence or metastases of
MTC. Further studies are warranted to investigate its value in
patient management. (2) In this small group of patients
tumour uptake of either 111In-DOTA-MG11 or 111In-DOTA-
CCK was less promising for imaging and was considered too
low to expect any beneficial effect from PRRT. To enable
therapy with CCK-2 receptor-binding radiolabelled analogues
further research is needed and should be aimed towards
designing stable compounds which retain high receptor
affinity but in addition have more favourable biodistribution
profiles including low renal retention.
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